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evaluated outcomes after TAVI with S3 THV with particular emphasis
on the updated Valve Academic Research Consortium (VARC-2)
criteria.
METHODS 261 consecutive patients undergoing transfemoral TAVI
with S3 THV at our center were enrolled and outcome according to the
VARC-2 criteria was analyzed at 30 days.
RESULTS Mean age was 816 years and median logistic EuroScore
was 12% [8-21]. Follow-up at 30 days was available for 260 pa-
tients. VARC-2 deﬁned device success was achieved in 251 (96%) of
patients; 5 (2%) cases developed moderate paravalvular leakage. At
30 days, one patient (0.4%) died due to a noncardiac cause and 8
(3%) patients suffered from a disabling (n¼4) or non-disabling
stroke (n¼4). Life-threatening bleeding and major vascular com-
plications occurred in 12 (5%) and 7 (3%) of the cases, respectively.
From discharge to 30 days, 5 (2%) patients were hospitalized due
to valve-related symptoms or worsening of heart failure. The
VARC-2 composite early safety endpoint at 30 days, all-cause
mortality, disabling and non-disabling stroke, life-threatening
bleeding, acute kidney injury, coronary artery obstruction requiring
intervention, major vascular complication, or valve-related
dysfunction requiring repeat procedure was observed in 23 (9%)
patients. Permanent pacemaker implantation rate at 30 days was
16% (38 of the 235 patients without pacemaker at baseline) and
with 30-days follow-up. Myocardial infarction, coronary obstruction
requiring intervention, valve-related dysfunction and endocarditis
were not observed.
Clinical outcome in-hospital and at 30 daysIn-hospital events
(n [ 261)At 30 Days*
(n [ 260)All-cause mortality 0 (0) 1 (0.4)Disabling stroke 3 (1) 4 (1.5)Non-disabling stroke 4 (2) 4 (1.5)Hospitalization for valve-
related symptoms or
worsened CHF- 5 (2)Major vascular complication 8 (3) 7 (3)Life-threatening bleeding 11 (4) 12 (5)AKI 2/3, including renal
replacement therapy5 (2) 4 (2)Coronary artery obstruction
requiring intervention0 (0) 0 (0)Myocardial infarction 0 (0) 0 (0)Valve-related dysfunction
requiring repeat procedure
(BAV, TAVI or SAVR)0 (0) 0 (0)Endocarditis (n, %) 0 (0) 0 (0)Valve thrombosis 0 (0) 0 (0)New pacemaker** 35 (15) 38 (16)VARC-2 early safety composite
endpoint at 30 Days- 23 (9)All data are absolute number (percentage)
Abbreviations: CHF ¼ Congestive heart failure; AKI ¼ Acute kidney injury; VARC ¼ Valve Academic Research
Consortium; *1 patient lost to follow-up, **excluding patients with prior pacemaker (n¼235)
CONCLUSIONS We found very good 30-day results using a novel
balloon expandable S3 THV with a low rate of severe clinical events
according to the VARC-2 composite early safety endpoint. The novel
balloon expandable S3 THV is associated with a high procedural suc-
cess rate and favorable early safety proﬁle considering the VARC-2
composite endpoint. The need for pacemaker implantations appears
to be more frequent than that seen with its predecessor.
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Tolochenaz, Switzerland; 3Wing Tech Inc., Irvine, CABACKGROUND Our objective was to estimate the impact of avail-
ability of transcatheter heart valve replacement (TAVR) therapy on
overall heart valve replacement volumes and aortic valve disease
mortality over a longer-term horizon, using the German healthcare
system as a reference case, which was among the ﬁrst systems
adopting TAVR therapy in routine care.
METHODS We collected therapy- and age-speciﬁc procedure vol-
umes from records of the German Federal Statistics Ofﬁce for TAVR
and surgical aortic valve replacement (SAVR) procedures for years
2009-2013. Relevant ICD-10 diagnosis-based information about dis-
charges and hospital-based mortality were obtained for the same
period. We computed therapy-speciﬁc and total procedure volumes
and growth stratiﬁed by 5-year age increments and in total.
Discharge and mortality data for aortic valve disease hospitaliza-
tions was assessed to obtain an estimate of changes in per-case
mortality.
RESULTS Overall procedure volumes grew from 26,466 in 2009 to
33,235 in 2013 (þ26%). This growth was driven by TAVR (3,411 to
10,814; þ217%), while SAVR volumes remained stable (23,055 to
22,421; -3%). In patients 75 years or older, an overall procedure
growth of 51% was observed (12,168 to 18,318), with volumes in
older patient segments growing more heavily (þ62% in >80-year
olds; þ101% in >85-year olds). Across all elderly age groups, SAVR
volumes decreased (-20% in >80 year olds; -37% in >85 year olds),
while they grew in selected younger patients groups (highest
growth þ30% in age group 60-64 yrs.). Concurrently, total aortic
valve disease hospital discharges grew by 26%, from 44,161 to
55,748, while mortality per hospitalization case decreased by 5%
between 2009 and 2013.
CONCLUSIONS Five-year real world data from the German healthcare
system demonstrate that the availability of TAVR has led to substantial
growth in aortic valve replacements. TAVR substantially increased
volumes in the elderly population, and partially replaced SAVR treat-
ments in this subgroup. Concurrently, increased therapy utilization in
patients previously left untreated was associated with a reduction in
overall mortality of aortic valve-related hospitalizations. Further
analysis is warranted to compare these data with the German Registry
as well as replicate them in other countries, if possible stratiﬁed by
pre-procedure surgical risk.
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BACKGROUND To overcome limitations of transapical and trans-
septal access to deliver large caliber transcatheter implants to the
mitral valve, we hypothesized that the left atrium could be accessed
through the posterior chest wall by displacing the lung with CO2 un-
der imaging guidance.
METHODS We tested fully percutaneous transthoracic left atrial ac-
cess in 12 animals (10 pigs and 2 sheep) and 3 human cadavers under
real-time magnetic resonance imaging (n¼10) or x-ray ﬂuoroscopy
plus C-arm computed tomographic (n¼2) guidance. We also simulated
transthoracic trajectories to the left atrium on human contrast-
enhanced cardiac computed tomographic angiograms.
RESULTS Animals were survived for median 7.5 days (Q1-Q3, 7–8.5
days). The pleural space was insufﬂated with CO2 to displace the
lung, an 18-26F sheath was delivered to the left atrium, and the left
atrial port was closed using an off-the-shelf nitinol cardiac occluder
(Amplatz Atrial Septal Occluder) successfully in 12/12 animals.
There was no procedural mortality and no important change in
hemodynamics (heart rate, mean arterial pressure and expired
CO2). Median bleeding into the pericardium and pleura were 55mL
(40–73mL) and 10mL (10–75mL) respectively, which were immedi-
ately auto-transfused.1 hemodynamically insigniﬁcant pericardial
effusion was observed at follow-up. We also successfully accessed
and closed the left atrium in 3 human cadavers under real-time
magnetic resonance (n¼1) or X-ray ﬂuoroscopic guidance (n¼2). A
theoretical trajectory to the left atrium, assuming the right lung
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tomographic angiograms analyzed.
CONCLUSIONS Percutaneous transthoracic left atrial access is
feasible in large mammals and in human cadavers under real-time
magnetic resonance or x-ray ﬂuoroscopic guidance. The presence
of potential transthoracic trajectories to the left atrium on
human cardiac computed tomographic analysis suggests clinical
translation is realistic. This technique could provide fully percuta-
neous access to deliver large caliber transcatheter mitral valve
implants.
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BACKGROUND A small number of Transcatheter Mitral Valve Im-
plants (TMVI) have been reported using devices designed to treatsecondary mitral regurgitation (MR). There are a number of technical
challenges for TMVI including device migration, left ventricular
outﬂow tract obstruction (LVOTO) and paravalvular MR. We report 6-
month outcomes of ﬁrst-in-man (FIM) implants with the Tendyne
Bioprosthetic Mitral Valve System.
METHODS Four patients (Table) deemed unsuitable for treatment
with any CE marked device by Heart Team Evaluation underwent
TMVI using a Tendyne system (a tri-leaﬂet porcine pericardial valve
in a tethered self-expanding nitinol frame, with an apical tether
ﬁxed to an epicardial pad to stabilize the device). The device is fully
repositionable and retrievable even after complete deployment.
Device size was chosen based on multidetector computed
tomography (MDCT) tomography to deﬁne mitral annular
dimensions, geometry and guide surgical access. Annular
dimensions were conﬁrmed by intra-operative 3-dimensional
transoesophageal echocardiography. The device was implanted
under TOE-guidance using general anesthesia via a transapical
approach through a small left mini-thoracotomy using a 34Fr sheath
which was advanced over the wire into the left atrium. The device
was advanced into the sheath, extruded, positioned into the correct
anatomical position by rotating the device, and fully deployed. The
apical pad was inserted into position over the tether. The tension on
the tether was then adjusted to optimize the position of the device.
The apical pad facilitated LV apical closure.
RESULTS TMVI procedures were performed between October 2014
and January 2015. All patients had no paravalvular MR, no trans-
valvular MR, and no transmitral gradient immediately after TMVI
(Table). One patient (who had previous mitral annuloplasty)
developed signiﬁcant LVOTO (95mmHg) associated with systolic
anterior motion of the mitral valve. Following LVOT stenting, LVOT
gradient decreased to 47mmHg. All 4 patients were discharged to
their own home, independent of activities of daily living. At 6-
months, all were alive, living independently at home, with no
further heart failure hospital admissions. All showed improvement
in functional capacity and 6-minute walk test. All valves were
stable, with reduction in tricuspid regurgitation and pulmonary
pressures. Two patients had evidence of mild paravalvular
regurgitation and were asymptomatic but with biochemical evidence
of hemolysis.Before TMVI Patient 1 Patient 2 Patient 3 Patient 4Age 68 75 87 75Previous CABG/
MV repairYes Yes No YesPre-TMVI NYHA
ClassIV IV III IIIPre-TMVI EROA
cm2
0.34 0.79 1.39 0.47Pulmonary
Pressure
(mmHg)104 61 75 45LVOT gradient
(mmHg)5 7 6 5Post-TMVI MR
gradeNone Trivial None NoneMean mitral
gradient
(mmHg)3 5 2 5LVOT gradient
(mmHg)8 10 6 47Length of
hospital stay
(days)16 8 8 65Discharge
destinationHome Home Home Home6-month Follow-
Up: AliveYes Yes Yes YesNYHA Class I I I IIDegree of MR on
echoNone Trivial None
